AU2005230676B2 - Nucleoside derivatives and therapeutic use thereof - Google Patents

Nucleoside derivatives and therapeutic use thereof Download PDF

Info

Publication number
AU2005230676B2
AU2005230676B2 AU2005230676A AU2005230676A AU2005230676B2 AU 2005230676 B2 AU2005230676 B2 AU 2005230676B2 AU 2005230676 A AU2005230676 A AU 2005230676A AU 2005230676 A AU2005230676 A AU 2005230676A AU 2005230676 B2 AU2005230676 B2 AU 2005230676B2
Authority
AU
Australia
Prior art keywords
tumors
compound
formula
mmol
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005230676A
Other languages
English (en)
Other versions
AU2005230676A1 (en
Inventor
Chang H. Ahn
Won J. Choi
Lak S. Jeong
Sang K. Lee
Young B. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rexahn Corp
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of AU2005230676A1 publication Critical patent/AU2005230676A1/en
Application granted granted Critical
Publication of AU2005230676B2 publication Critical patent/AU2005230676B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2005230676A 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof Expired AU2005230676B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55814104P 2004-04-01 2004-04-01
US60/558,141 2004-04-01
PCT/US2005/011313 WO2005097757A2 (en) 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof

Publications (2)

Publication Number Publication Date
AU2005230676A1 AU2005230676A1 (en) 2005-10-20
AU2005230676B2 true AU2005230676B2 (en) 2010-10-07

Family

ID=34979006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005230676A Expired AU2005230676B2 (en) 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof

Country Status (15)

Country Link
US (1) US7405214B2 (enExample)
EP (1) EP1732902B1 (enExample)
JP (2) JP5001832B2 (enExample)
KR (1) KR100926596B1 (enExample)
CN (2) CN1980898B (enExample)
AT (1) ATE453628T1 (enExample)
AU (1) AU2005230676B2 (enExample)
BR (1) BRPI0509553B8 (enExample)
CA (1) CA2562965C (enExample)
DE (1) DE602005018620D1 (enExample)
ES (1) ES2334803T3 (enExample)
IN (1) IN2014DN04587A (enExample)
MX (1) MXPA06011141A (enExample)
PL (1) PL1732902T3 (enExample)
WO (1) WO2005097757A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315534B2 (en) * 2007-08-10 2016-04-19 Board Of Regents Of The University Of Nebraska Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents
EP2515650A4 (en) * 2009-12-23 2013-05-29 Univ Nebraska TARGETED RADIOACTIVELY MARKED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER
AU2014232502B8 (en) 2013-03-15 2018-01-18 Rexahn Pharmaceuticals, Inc. Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
EP3307251B8 (en) * 2015-06-09 2021-12-01 Ocuphire Pharma, Inc. Fluorocyclopentenylcytosine uses and processes of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187674A (ja) * 1984-10-06 1986-05-06 Yoshitomi Pharmaceut Ind Ltd シクロペンテン環を有する新規ヌクレオシド
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
JP2004533406A (ja) * 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds

Also Published As

Publication number Publication date
MXPA06011141A (es) 2007-08-14
WO2005097757A2 (en) 2005-10-20
PL1732902T3 (pl) 2010-06-30
EP1732902B1 (en) 2009-12-30
US20050222185A1 (en) 2005-10-06
CN1980898A (zh) 2007-06-13
BRPI0509553B1 (pt) 2019-06-18
CA2562965C (en) 2013-10-29
EP1732902A2 (en) 2006-12-20
KR20070012685A (ko) 2007-01-26
CN102091072A (zh) 2011-06-15
US7405214B2 (en) 2008-07-29
CA2562965A1 (en) 2005-10-20
BRPI0509553B8 (pt) 2021-05-25
CN1980898B (zh) 2011-01-12
ATE453628T1 (de) 2010-01-15
JP5001832B2 (ja) 2012-08-15
IN2014DN04587A (enExample) 2015-07-10
ES2334803T3 (es) 2010-03-16
JP2012107072A (ja) 2012-06-07
DE602005018620D1 (de) 2010-02-11
KR100926596B1 (ko) 2009-11-11
WO2005097757A3 (en) 2005-12-08
AU2005230676A1 (en) 2005-10-20
JP2007531736A (ja) 2007-11-08
BRPI0509553A (pt) 2007-09-18

Similar Documents

Publication Publication Date Title
EP4333850A1 (en) Shp2 inhibitor monotherapy and uses thereof
US8404698B2 (en) Quinazoline derivatives and therapeutic use thereof
KR20120083492A (ko) 신규 5-플루오로우라실 유도체
WO2017152706A1 (zh) 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
KR20250110848A (ko) Sting 작용제로서 헤테로사이클릭 화합물
JP2012107072A (ja) ヌクレオシド誘導体およびそれらの治療用途
RU2656485C2 (ru) Дейтерированные соединения хиназолинона и содержащие их фармацевтические композиции
JP2020023441A (ja) Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
AU2018306726B2 (en) Anticancer drugs and methods of making and using same
US20130245275A1 (en) Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
CN120202181A (zh) Cd73抑制剂的药物形式
JPS62919B2 (enExample)
EP3914241A1 (en) Anticancer drugs and methods of making and using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired